Phase 4 N=49 Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive Disorder
Depression · Bipolar Disorder
Primary: MADRS Improvement Over 6 Weeks — 10.0; 6.7 units on a scale — p=0.48
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=588 A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant
Depressive Disorder, Major
Primary: Double Blind (DB) Treatment Phase: Change From Baseline to Day 43 in Montgomery- Asberg Depression Rating Scale (MADRS) Total Score- Estimand 1 — -10.5; -12.9 Units on a…
N/A N=63 Digital Intervention to Treat Anxiety and Depression Among Persons Receiving Treatment for Opioid Use Disorder
Opioid-use Disorder · Anxiety Disorders · Depressive Disorder
Primary: Change in Anxiety Symptoms as Assessed by Generalized Anxiety Disorder- Q-IV Scale — -1.8; -1.04; -2.47; -1.53 units on a scale — p=.755
Phase 2 N=287 A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
Depressive Disorder, Major
Primary: Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -12.3; -12.2; -15.0; -14.7 score on a scale — p=0.724
Phase 2 N=48 Double-Blind Treatment of Major Depressive Disorder With Vilazodone
Major Depressive Disorder
Primary: Montgomery-Åsberg Depression Rating Scale (MADRS) — 13.9; 12.7; 14.5; 13.2 units on a scale — p=0.342
Phase 2 N=73 Safety Study of Ziprasidone (Geodon) for the Depressive Mixed State
Bipolar Disorder · Bipolar Depression · Depression
Primary: The Primary Outcome Measure Was Change in Montgomery-Asberg Depression Rating Scale (MADRS) Scores Over Weeks Between Groups. — 11.4; 5.9 Scores on a scale
Phase 2 N=180 A Definitive Estrogen Patch Study (ADEPT)
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder(Not in Manic Phase)
Primary: Positive and Negative Syndrome Scale (PANSS) — 18.24; 19.18; 18.18; 14.11 units on a scale
Phase 3 N=1,480 A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Major Depressive Disorder (MDD)
Primary: Change From Randomization to Week 8 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -9.36; -9.59; -9.36 units on a scale — p=0.997
Phase 3 N=1,416 A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Randomization to Week 8 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -8.47; -8.70; -7.77 units on a scale — p=0.338
Phase 2 N=193 An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder
Depressive Disorder, Major
Primary: Change From Baseline in Hamilton Depression Rating Scale (HDRS-17) Total Score at Week 12 — -10.6; -11.4 Units on a scale — p=0.310
Phase 3 N=1,304 A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder
Depressive Disorder, Major
Primary: Time to First Relapse During the First 52 Weeks of the Double-Blind Treatment Period — 232; 225; 336 Days — p=0.5305
Phase 3 N=513 A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
Depressive Disorder, Major · Anhedonia
Primary: Change From Baseline to Day 43 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -11.4; -12.3 Units on a scale — p==0.467
N/A N=304 Comparing Individual Therapies for Veterans With Depression, PTSD, and Panic Disorder
Major Depressive Disorder · Posttraumatic Stress Disorder · Panic Disorder and Agoraphobia
Primary: PTSD Checklist for DSM-5 (PCL-5) — 48.0; 46.37; 42.44; 36.95 score on a scale
Phase 2 N=257 Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Bipolar I Depression
Primary: The Mean Change From Baseline to Endpoint (Week 8 or Last Observation After Baseline) in the 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30)…
Phase 2 N=70 Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence
Depressive Disorder, Major · Cannabis Abuse
Primary: Days Per Week of Cannabis Use. — 3.88; 3.1 Days of cannabis use per week — p=<0.05